SCHEMBL10106951

SCHEMBL10106951

COC(=O)c1c2c(c3ccccc3c1OC)OC(c1ccc(C)cc1)(c1ccc(OC)cc1)C=C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
EGFR P00533 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 4/20 0.36
CYP2C19 P33261 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TP53 P04637 2/20 0.33
HTT P42858 1/20 0.33
EDNRA P25101 1/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169861 0.96 ATM (0.41) ATML3MBTL1EGFRTDP1SMN1; SMN2
SCHEMBL10102254 0.91 ATM (0.39) ATML3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL7001887 0.88 EGFR (0.41) ATML3MBTL1EGFRSMN1; SMN2ALDH1A1
SCHEMBL15254539 0.88 KDM4E (0.39) ATML3MBTL1EGFRTDP1ALDH1A1
SCHEMBL8978679 0.88 SMN1; SMN2 (0.34) ATML3MBTL1EGFRTDP1SMN1; SMN2
SCHEMBL8978512 0.88 ATM (0.41) ATML3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL9280386 0.87 ATM (0.38) ATML3MBTL1EGFRTDP1SMN1; SMN2
SCHEMBL21452904 0.86 ATM (0.42) ATML3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL13464551 0.86 SMN1; SMN2 (0.38) ATML3MBTL1TDP1SMN1; SMN2ALDH1A1
SCHEMBL29565080 0.85 ATM (0.41) ATML3MBTL1TDP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 ATM 615/4885L3MBTL1 165/4885EGFR 2969/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 ATM 2587/4885L3MBTL1 1486/4885EGFR 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.